Know Cancer

or
forgot password

Evaluating the Risk of Serious Ventricular Arrhythmia and Sudden Cardiac Death Among Users of Domperidone


N/A
N/A
N/A
Not Enrolling
Both
Arrhythmias, Cardiac

Thank you

Trial Information

Evaluating the Risk of Serious Ventricular Arrhythmia and Sudden Cardiac Death Among Users of Domperidone


The purpose of this population-based, observational study is to evaluate the combined risk
of serious ventricular arrhythmia (irregular heart rhythm) and sudden cardiac death in users
of domperidone (a medication used to treat certain gastrointestinal disorders) compared with
users of proton pump inhibitors (another group of medications used to reduce gastric or
stomach acid production. The study will be conducted using patient information from
Saskatchewan Health (SH) who had recorded dispensings of domperidone or a PPI from 1990
through 2005. The first objective of the study is to estimate the combined relative risk of
the occurance of a particular type of irregular heart rhythm known as serious ventricular
arrhythmia (SVA) and sudden cardiac death SCD (defined as a natural death from an
unexpected circulatory arrest) during current use of domperidone or current use of proton
pump inhibitors (PPIs) as compared with nonuse in a diabetic population. The second
objective is to estimate the combined relative risk of SVA and SCD during current use of
domperidone or current use of PPIs as compared with nonuse in a non-diabetic population.
Study drug dosing information not required for Observational Study


Inclusion Criteria:



- Saskachewan residents who received domperidone or a proton pump inhibitor (PPI)
between January 1, 1990, and December 31, 2005

Exclusion Criteria:

- Cancer free >=1 year of history in the database before receiving the first dose of
domperidone or a PPI

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Retrospective

Outcome Measure:

The occurance of serious ventricular arrhythmia and sudden cardiac death (combined end point)

Outcome Time Frame:

Retrospective study

Safety Issue:

Yes

Principal Investigator

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial

Investigator Role:

Study Director

Investigator Affiliation:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Authority:

United States: Institutional Review Board

Study ID:

CR016396

NCT ID:

NCT00925457

Start Date:

Completion Date:

December 2005

Related Keywords:

  • Arrhythmias, Cardiac
  • Serious ventricular arrhythmia
  • Sudden cardiac death
  • Domperidone
  • Case-control study
  • Saskatchewan residents
  • Observational Study
  • Arrhythmias, Cardiac
  • Death, Sudden, Cardiac
  • Death

Name

Location